New spatial twist, Illumina StrataMap Spatial Solution targets multi-omics labs

Illumina’s new StrataMap Spatial Solution bundles chemistry, software and workflows to bring spatial transcriptomics and proteomics onto existing NovaSeq X systems, aiming squarely at high-throughput clinical and translational research labs.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 4:24 AM ET. Details in the imprint.

With the new StrataMap Spatial Solution, Illumina is moving to lock spatial biology workflows directly onto its flagship NovaSeq X sequencing platforms, bundling reagents, imaging, software and analysis into a single spatial multi-omics package aimed at high-throughput research labs. According to Illumina, the system is designed to let users run whole-slide spatial RNA and protein assays and then read them out on existing NovaSeq X instruments rather than buying a standalone spatial imaging rig. Illumina’s launch announcement describes StrataMap as a complete solution spanning sample prep through cloud-based analysis.

What Illumina’s StrataMap Spatial Solution actually brings to the bench

StrataMap is positioned as a modular spatial biology workflow that combines slide processing chemistry, a benchtop imaging instrument and dedicated analysis software, with the sequencing portion handled by a connected NovaSeq X or NovaSeq X Plus in the same lab. Illumina outlines that the workflow starts with tissue sections on specialized slides, where in situ barcoding and labeling capture spatially resolved RNA and protein signals that can later be decoded via sequencing on NovaSeq X, allowing users to overlay gene expression and protein abundance data on histology-like images of the same tissue. The official product page highlights compatibility with NovaSeq X systems and emphasizes support for both discovery research and translational projects.

For US customers, Illumina is marketing StrataMap toward large academic centers, oncology consortia and pharma discovery groups that already operate NovaSeq X fleets and are looking to add spatial resolution without migrating to a separate imaging-centric platform. Independent industry coverage notes that Illumina is entering a crowded spatial biology field that includes players like 10x Genomics and NanoString, but with the specific angle of leveraging installed Illumina sequencers and Illumina Connected Analytics for data processing rather than introducing a completely new hardware ecosystem. A recent NGS industry newsletter described StrataMap as Illumina’s bid to keep spatial sequencing volume on NovaSeq X instead of letting it move to rival platforms.

At a strategic level, StrataMap fits Illumina’s pattern of packaging instruments, reagents and software into integrated workflows that tie closely to its highest-throughput sequencers, seeking to expand addressable applications like oncology, immunology and neurology with spatial context while also defending its share of sequencing consumables. Shares of Illumina (US4523271090) traded on NASDAQ at about $115 in mid-June 2026.

Illumina StrataMap Spatial Solution in brief

• Product: StrataMap Spatial Solution
• Manufacturer: Illumina Inc.
• Category: New Release / Launch (spatial multi-omics workflow)
• Launch date: Mid-June 2026 (announced globally)
• MSRP / Price: Not publicly disclosed; marketed for high-throughput labs using NovaSeq X
• Availability: Offered through Illumina sales channels in major research markets, with focus on labs already running NovaSeq X platforms
• Target audience: Academic medical centers, translational research institutes, pharma and biotech discovery groups working on oncology, immunology and complex tissue biology
• Key differentiator / USP: Integrates spatial RNA and protein profiling into existing NovaSeq X workflows, combining chemistry, imaging and cloud analysis instead of requiring a separate spatial imaging ecosystem

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.